Chimerix Announces Presentation of Multiple Imipridone Datasets at American Association for Cancer Research Annual Meeting
DURHAM, N.C., April 18, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced a summary of presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023 in Orlando, FL.
- “We are delighted to share multiple datasets related to our imipridone platform’s potential at this year’s AACR annual meeting among leading cancer researchers,” said Mike Sherman, Chief Executive Officer of Chimerix.
- Other presentations at the conference highlighted preclinical oncology studies related to the imipridone platform performed by Chimerix and collaborators at the Brown University Cancer Center.
- The ongoing ACTION trial, a global Phase 3 clinical trial of ONC201 in newly diagnosed H3 K27M-mutant diffuse glioma, was also highlighted.
- Further information regarding the data presented at AACR can be found on the Publications page of the Chimerix corporate website.